# Boostimmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/boostimmune

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.boostimmune.com
- Total disclosed funding: $13M
- Latest round: Series A (Jun 23, 2022)
- Investors on record: 8

## About

In 2021, the company was co-founded by Kwanghee Lee, a biotech/pharma professional, and Tadatsugu Taniguchi, an immunologist. In 2022, the company closed series A round of funding, raising SKR 17 million, which will be used for the pre-clinical entry of the leading BIO-101 project and the production of samples for clinical trials.

The company operates as a drug developer focuses on anti-cancer field. Up till 2023, the company has the pipeline of 3 in the lead stage -- BIO101 (anti-TCTP antibody), BIO103 (ADC), BIO105, and three in discovery stage -- BIO104, BIO106, BIO107.

The company plans to apply for a clinical trial application (IND) to the US FDA by the end of 2023.

## Funding rounds

- Series A, Jun 23, 2022, $13M — Mirae Asset Global Investments, AJU IB Investment, Smilegate Investment, SV Investment, Company K Partners, Premier Partners, Time Folio Asset Management, We Venture Partners

## Investors

- Mirae Asset Global Investments (https://capitalatlas.ai/funds/mirae-asset-global-investments) — Series A
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series A
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A
- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series A
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series A
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series A
- Time Folio Asset Management — Series A
- We Venture Partners (https://capitalatlas.ai/funds/we-venture-partners) — Series A